Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The antiemetic effect of prednisolone on nausea/vomiting was investigated in 67 patients with advanced prostatic cancer and a performance status of < or = 2. The study was a double-blind, placebo-controlled, randomized trial with a parallel group design. The objective was to compare the incidence and severity of nausea/vomiting between the two groups. Prednisolone or placebo was given twice daily for 3 weeks with the dose decreased during the third week from 15 mg/day to 10 mg for 3 days and finally to 5 mg/day during the last 4 days. EMP was given as two 140 mg capsules daily for 3 days at the beginning, then as four capsules for 4 days followed by six capsules for 21 days. Areas under curves (AUCs) for nausea and for nausea/vomiting scores were calculated based on the patient's diary notes: nausea (0-3), vomiting (0-6), nausea/vomiting (0-9). Control of emesis in terms of complete, moderate or poor control was registered. Pretreatment characteristics were evenly balanced. The results indicated that no statistical differences between the two groups of patients were present in AUCs for weeks 1-3 or weeks 1-4. We conclude that it was not possible to demonstrate a significant antiemetic efficacy of prednisolone. However, in all but one case the patients in the prednisolone group could be treated for at least 3 weeks without any major incidents of nausea/vomiting.
 ...
PMID:Antiemetic efficacy of prednisolone: a placebo-controlled trial in patients with advanced prostatic cancer treated with estramustine phosphate. 960 80

Prednisolone monotherapy has been the standard systemic treatment in many patients with androgen- independent prostate cancer and should today be compared to treatment with Taxotere plus prednisolone. One hundred and thirty four patients were entered into a randomized phase II study [arm A: Taxotere plus prednisolone (30 mg/m2 weekly during 5 of 6 weeks + prednisolone 5 mg orally twice daily); arm B: prednisolone (5 mg orally twice daily)]. Biochemical response at 6 weeks was the primary outcome parameter, with progression-free and overall survival as secondary outcomes. Biochemical response at 6 weeks was recorded in 29 of 54 evaluable patients in arm A [54%; 95% confidence interval (CI) 40-67%] and 13 of 50 patients in arm B (26%; 95% CI 14-38%), with a similar difference in response rates at 12 weeks. Median progression-free survival was 11 months in arm A (95% CI 5.8-16.2)and 4 months in arm B (95% CI 2.4-5.6). Median overall survival was 27 months in arm A (95% CI 19.8-34.1) and 18 months in arm B (95% CI 15.2-20.8). Assessment of pain and quality of life showed superiority of arm A treatment, without unacceptable toxicity. Taxotere plus prednisolone is recommended as systemic standard treatment in androgen-independent prostate cancer.
 ...
PMID:A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer. 1854 92